cytochrome P450 family 39 subfamily A member 1Genealiases: []
Q-omics provides the consensus-scored CYP39A1 profile across patient tissues and cancer cell-line models. CYP39A1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CYP39A1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, CYP39A1 RNA expression shows 16,757 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where CYP39A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP39A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP39A1 survival associations across molecular data types. CYP39A1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP39A1 RNA expression–survival associations across cancer types. High CYP39A1 expression shows unfavorable associations in LGG and LUAD, but favorable associations in KIRC, UVM, SKCM and PRAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CYP39A1 RNA expression.
This table summarizes CYP39A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CYP39A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP39A1 shows lower tumor expression in KIRC, BLCA, LUAD, KICH, LIHC and LUSC. The KIRC box plot shows higher CYP39A1 RNA expression in normal versus tumor tissue (log2 FC = −2.022, t-test p < 0.001).
This table shows molecular features associated with CYP39A1 in patient tissues and cancer cell lines. In patient samples, CYP39A1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP39A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
